Clinical Conditions And Cardiac Function: Correlations With Left Atrial Fibrosis By Mri In Subjects With And Without Atrial Fibrillation by Grunseich, Karl
Yale University 
EliScholar – A Digital Platform for Scholarly Publishing at Yale 
Yale Medicine Thesis Digital Library School of Medicine 
1-1-2016 
Clinical Conditions And Cardiac Function: Correlations With Left 




Follow this and additional works at: https://elischolar.library.yale.edu/ymtdl 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Grunseich, Karl, "Clinical Conditions And Cardiac Function: Correlations With Left Atrial Fibrosis By Mri In 
Subjects With And Without Atrial Fibrillation" (2016). Yale Medicine Thesis Digital Library. 2052. 
https://elischolar.library.yale.edu/ymtdl/2052 
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A 
Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital 
Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more 






Clinical Conditions and Cardiac Function: Correlations with Left Atrial 




A Thesis Submitted to the  
Yale University School of Medicine  
in Partial Fulfillment of the Requirements for the 





















The purpose of this study was to evaluate the clinical conditions and cardiac 
functions associated with left atrial (LA) fibrosis by late gadolinium enhancement 
(LGE). LA LGE has been found to be associated with various measures of 
cardiac functions, procedural outcomes, and adverse events in patients who 
already have atrial fibrillation (AF). Assessment of LA fibrosis by LGE in patients 
without AF has largely been unexamined and comparison of these patients to 
those with AF could prove useful. This study was a retrospective chart and 
imaging review of 137 consecutive subjects imaged with a 3D LGE sequence at 
one institution from 2012-2014. Fibrosis by LA LGE is elevated in subjects with 
congestive heart failure (CHF), AF, hypertrophic cardiomyopathy (HCM), and 
mitral regurgitation when compared to a set of reference subjects (all p < 0.05). 
In multivariate analysis, HCM (p = 0.01) and CHF (p < 0.01) were independently 
associated with elevated LGE. Across all subjects, LA LGE was moderately 
correlated with minimum LA volume (r = 0.41, p < 0.01) and LA ejection fraction 
(r = -0.43, p < 0.01) but weakly correlated with maximum LA volume (r = 0.197, p 
= 0.02); these relationships were similar in subgroups with and without AF. In a 
subset of subjects without AF, there was a lower active atrial ejection fraction 
with increasing LA LGE (r = -0.438, p < 0.01). Also, after multivariate adjustment 
for ventricular filling measures, there was an independent association of 
increased LA LGE with decreased passive LA emptying (p = 0.02). Subjects with 
heart failure but ventricular ejection fraction >45% had greater LA LGE than 




We found that extent of LGE correlates with the presence of CHF, AF, HCM, 
mitral regurgitation, and some cardiac anatomic and functional measurements.  
This study lays the groundwork for further evaluation of the utility of measuring 
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Atrial Fibrillation: Prevalence and Pathogenesis 
Atrial fibrillation (AF) is the most common sustained arrhythmia in patients 
worldwide. In the United States, over 3 million people were estimated to have AF 
in 2005 with a continuing increase in prevalence that could reach 7 million by 
20501. AF has an incidence that increases with age and is associated with 
symptoms of palpitations, dyspnea (when associated with congestive heart 
failure (CHF)) and thromboembolic disease. The increased risk of 
thromboembolic disease results from ineffective atrial contraction caused by the 
disorganized electrical activity in the atria and associated stasis of the atrial 
blood. Stroke, visceral, and peripheral ischemia are significant contributors to AF 
related morbidity and mortality. Clinical management of AF is based on either 
heart rate or rhythm control, and management of thromboembolic risk with 
anticoagulants such as warfarin or newer factor X inhibitors. This management 
carries its own risk of bleeding, which must be carefully weighed against risks of 
thromboembolism. 
 The pathogenesis of AF is related to a trigger (an abnormal focus of 
electrical generation) and a substrate (the atria). It is known that the trigger is 
closely associated with the pulmonary veins as electrophysiological studies have 
determined this area is capable of repetitive firing, and the veins have been 
found to be the site of stretch sensitive ion channels2,3. Once triggered, the 
substrate must have some qualities that allow the electrical activity to persist, or 




duration and a short refractory period that becomes even shorter with an 
increasing rate of depolarization4. These qualities alone make the atria an ideal 
site for maintaining aberrant electrical activity. Additionally, atrial remodeling is 
thought to contribute to abnormal conduction pathways in the atria that lead to 
the development of self-sustaining rotors of spiraling electrical activity3,4. While 
some remodeling from other cardiac disease may contribute to the initial 
development of AF, episodes of AF are known to contribute to remodeling in a 
way that reinforces aberrant electrical activity5 and alters electrophysiological 
properties of the atrial tissue6. This is why paroxysmal AF tends to progress to 
persistent AF which then becomes harder to terminate and manage from the 
physician’s standpoint.  
Remodeling of the left atrium (LA) on pathology studies has been shown 
to be associated with a variety of cardiac conditions, including AF5,7,8, mitral 
regurgitation9,10, and CHF11. Many of these studies have been necropsy studies 
or been done in animal models as, until relatively recently, there was no way to 
quantify atrial fibrosis in vivo. As these conditions have significant overlap with 
the clinical risk factors of AF development mentioned later, there could be 
potential value in determining whether atrial fibrosis could be used as an 
independent risk factor for later AF development or used as a guide to disease 
management by a physician.  
Left Atrial Fibrosis by MRI: Late Gadolinium Enhancement 
 Within the last 10 years, cardiac MRI sequences with late gadolinium 




briefly discuss the imaging methodology, in MRI studies, gadolinium is 
administered as a chelated ion that shortens the relaxation time of nearby 
protons on T1 weighted sequences in the areas where the molecule in 
concentrated. Immediately after IV administration, the concentration of 
gadolinium is highest in the blood when compared to other tissues. However, 
after time for mixing throughout the blood pool, the gadolinium compounds 
redistribute into the extracellular space, particularly in regions of tissues that are 
fibrotic or edematous. In cardiac imaging, scan parameters can be chosen that 
“null” normal cardiac tissue causing it to have low signal intensity, while areas of 
myocardium accumulating gadolinium have increased signal intensity. On an 
image, these areas appear dark or bright (respectively). This technique has long 
been used in cardiac MRI to examine regions of the ventricle affected by prior 
infarction, sarcoidosis, and various other forms of cardiomyopathy. 
Technical limitations of cardiac MRI limited the ability to use this technique 
in the thin-walled atria until more recently. The heart is almost always in motion 
either from its own electro-mechanical pumping function or nearby motion of the 
lungs and diaphragm. Although there are times during the cardiac cycle when it 
is moving less rapidly, this motion has always presented a challenge to the 
spatio-temporal resolution of cardiac MRI, particularly in patients with arrhythmia. 
To minimize these effects, gating techniques that utilize a subject’s EKG and 
chest diameter ensure cardiac imaging data are acquired within a narrow range 
of acceptable boundaries, in the current technique, when cardiac motion is 




xy plane using phase and frequency encoding with a slice selection pulse. In 
order to accurately identify and quantify late gadolinium enhancement in the 
atria, data need to be acquired throughout the entire atria concurrently, which 
requires encoding and acquisition in the x, y, and z dimensions simultaneously. 
This 3D technique with the aforementioned gating to select for mid-late 
ventricular diastole is used to image the entire left atrium for areas of T1 
enhancement due to accumulation of extracellular gadolinium (see Figures 1B, 
2).  
LGE on cardiovascular MRI has been used to characterize areas of 
fibrosis in the LA in patients with atrial fibrillation and has been associated with 
various metrics and outcomes12,13. For example, LA LGE both before and after 
pulmonary vein isolation is associated with rates of AF recurrence14,15. Areas of 
LGE have been associated with lower endocardial voltage16,17. Additionally, 
greater LA LGE has been found to be associated with stroke risk18, time in AF, 
pattern of AF19, and changes in atrial functional measurements20. This LGE 
detected fibrosis is suspected to underlie the remodelling previously described, 
which leads to the persistence of aberrant electrical activity in the atria in patients 
with AF. However, it has yet to be firmly demonstrated that locations of atrial 
fibrosis are directly correlated with locations of self-sustaining rotors of electrical 
activity.  
Risk factors for Atrial Fibrillation 
Current theory regarding the development and maintenance of AF is 




between impulses generated by aberrant tissue in the region of the pulmonary 
veins and a remodeled, fibrotic, and electrically susceptible atrial substrate3,5. LA 
LGE is a noninvasive measurement of one of these AF drivers but its association 
with risk of developing AF has not been described.  
Many different clinical factors have been tied to the risk of developing 
atrial fibrillation. The most common risk factor is hypertension but other factors 
such as other heart disease, obesity, diabetes, hyperthyroidism, chronic kidney 
disease, family history, heavy alcohol use, and pericardial fat, among others, 
have been found to be associated with increased risk of having AF1,21-25. One 
strongly associated cardiac lesion with AF is valvular disease, specifically mitral 
stenosis and mitral regurgitation which have been found to be associated with 
with a relative risk of AF as high as 2.42 (Table 1)26.  
Age, LA size, CHF, and hypertrophic cardiomyopathy (HCM) also stand 
out as particularly high-risk associations with AF21,26,27. There is also a general 
association with these conditions and ventricular diastolic dysfunction, and the 
link between diastolic dysfunction and AF has become better recognized 
recently28. Although associated with AF, these other clinical factors have not yet 
been associated with the primary development of atrial fibrosis by MRI. 
Atrial function and ventricular dynamics 
One correlate of atrial remodeling is atrial function, both passive and 
active.  Below we present data on the relationship between atrial function and 
atrial fibrosis.  However, any analysis of atrial dynamics cannot be considered 




filling and left atrial emptying. Atrial emptying, like ventricular filling, happens in 
three parts under normal physiologic conditions. 1) An early passive phase that 
begins immediately after isovolumetric relaxation of the left ventricle when the 
mitral valve opens and blood flows from a full left atrium to an “empty” left 
ventricle. This flow of blood is very rapid. 2) A mid diastolic phase when blood 
fills both the left atrium and ventricle from the pulmonary veins while the mitral 
valve is open. The flow of blood through the valve is slow and this phase is also 
called the conduit phase. 3) A late, active phase caused by contraction of the left 
atrium which forces more blood into the left ventricle immediately prior to mitral 
valve closure and ventricular contraction. Figure 3 displays the volume of the LA 
during the cardiac cycle. 
There are multiple well-established metrics for evaluating diastolic filling of 
the left ventricle on echocardiography. These include the peak filling rate (PFR) 
of blood flow through the mitral valve during early filling, the time from the 
beginning of diastole until this peak occurs (time to PFR), the estimated time 
from this peak until blood slows during mid diastole (deceleration time), ratios of 
initial filling velocity to tissue movement (E/e’) and late filling velocity (E/A) are 
just a few. Though well established for echocardiography, measures of diastolic 
function for cardiac MRI are relatively new and attempt to quantify surrogates of 
the echocardiographic measures because equivalent measures are challenging 
to achieve on MRI (Figure 4)29. Consider flow velocity through the mitral valve. 
While phase contrast imaging can be used to quantify flow through a plane that 




movement of the mitral valve during ventricular filling. This challenge limits the 
utility of using this technique in clinical scanning, especially when an ultrasound 
is cheaper and better able to measure flow with Doppler. Additional measures of 
diastolic function on cardiac MRI are limited by temporal resolution or the use of 
special tissue tracking techniques that have to be applied at the time of image 
acquisition29. 
The surrogates of echocardiographic diastolic function used in cardiac 
MRI rest primarily upon changes in the volume of the left ventricle30. The ability of 
cardiac MRI to accurately define ventricular volumes, detailing papillary muscles 
and endocardial trabeculations, is one of the method’s strengths (Figure 5). 
Although temporal resolution imposes some limitation on accuracy, ventricular 
filling rates can be estimated from changes in ventricular volume over time and 
be divided into the three phases mentioned earlier. Again, this is a surrogate for 
directly measured flow velocities for a few reasons. One is that velocity through 
the valve will be dependent on more than just the volume flowing through it and 
will be related to parameters such as pressure gradients and valve area. Also, 
this MRI approximation is a good surrogate only when aortic regurgitation is 
minimal or non-existent so that this volume does not contribute significantly to the 
end-diastolic volume. Regardless of their limitations, these measures of diastolic 
function, discussed in the methods and discussion, are used in the current study 
and the vast majority of studies, because they were the only ones available for 
the most of our subjects.  




Irrespective of the imaging modality used, combinations of these 
measures have also been used to identify different stages and degrees of 
diastolic dysfunction. From a physiological standpoint, diastolic dysfunction 
progresses from impaired myocyte relaxation to reduced ventricular wall 
compliance. Briefly, impaired relaxation leads to slower early filling rates with 
relatively greater contributions from left atrial contraction. As the dysfunction 
progresses, the ventricle begins to act like a stiffened spring, and after 
contraction, the unusually thickened myocardium rapidly springs open and fills 
quickly, early. Ventricular filling pressures are then high and relatively less blood 
enters the ventricle during the mid diastolic, “conduit” phase. Atrial contraction 
does little to contribute to ventricular end diastolic volume as it is pushing into a 
stiffened ventricle under higher pressure. These changes affect 
echocardiographic measures in well-established, predictable ways that generally 
allow for classification into grade 1, 2, or 3 diastolic dysfunction for a given 
subject. Classification of diastolic dysfunction based on the surrogate MRI 
metrics of diastolic dysfunction is new and less able to distinctly classify subjects 
into each of the three established grades31. Regardless of this issue, cardiac MRI 
studies have been able to show that increased left ventricular pressures, which 
can occur with diastolic dysfunction, do affect left atrial emptying dynamics32. 
This supports our hypothesis that diastolic dysfunction may also affect left atrial 
fibrosis. 




Mitral regurgitation is a risk factor for the development of atrial fibrillation 
likely mediated by its effect on atrial remodelling, increased volume, and fibrosis 
development9,10,33. However, within AF subjects, the association of mitral 
regurgitation with LA LGE is not well described. In spite of knowledge of the role 
of mitral regurgitation in AF development, recent histopathology data of the left 
atrial appendage of AF patients suggest that LA fibrosis is less prevalent in 
subjects with mitral regurgitation compared to those with mitral stenosis34. 
Further, another data set with few subjects does not show a relationship between 
mitral regurgitation and LA LGE among AF patients35. We hypothesized that 
increasing MR would result in increased LA LGE and examined this relationship 
in a cohort with mitral regurgitation and AF. 
 
Statement of Purpose/Aims 
Despite its value in patients already found to have AF, patterns of LA LGE 
in patients without AF have remained largely unexamined until very recently36. 
Cochet el al found that, other than AF, LA LGE was associated with age and 
structural heart disease36. In the current study, we examined the relationship 
between LA LGE, particular clinical conditions, and measures of cardiac function 
(atrial and ventricular, active and passive) in a population of patients with and 
without AF. We hypothesized that patients with clinical risk factors of atrial 
fibrillation such has CHF, HCM, enlarged LA, and ventricular diastolic dysfunction 




hypothesized that increased atrial fibrosis would reduce the active and passive 
emptying of the left atrium. 
 
Methods 
Patient Population and Clinical Data 
This study was an IRB approved, retrospective review of all subjects imaged with 
a late enhancement cardiac MRI sequence at our institution from 2012 to 2014. 
Indications for imaging were diverse (Table 2) as this LGE sequence was 
acquired as an added component of standard cardiac MRI protocols.  After initial 
identification of subjects in our PACS data-base, chart review of the electronic 
medical record was conducted to extract subjects’ clinical information from 
physician notes. Additionally, routine quantitative data describing cardiac 
structure and function was obtained from the clinical imaging report including LV 
end-diastolic volume (EDV), end-systolic volume (ESV), and ejection fraction 
(EF). Of the 304 subjects initially identified, those who had a prior sternotomy or 
catheter ablation of any type (28), or who were age 20 and younger (46), were 
excluded. An additional 93 subjects were excluded due to assessment of poor 
image quality (e.g. excessive motion artifact, poor contrast, or poor inversion time 
choice), resulting in a final study population of 137 subjects. 
 
Cardiac Imaging and Measurements 
Cardiac imaging was performed on Siemens 1.5T MR scanners at our institution 




ventricular diastole using an ECG-triggered and navigator-gated, fat-saturated 
3D gradient echo inversion recovery sequence, 15-25 minutes after 
administration of 0.2mmol/kg gadolinium contrast agent (Gadobutrol, Bayer 
Healthcare, Leverkusen, Germany). Voxel size was 1.32 x 1.32 x 3.0 mm3 with 
interpolation to 0.66 x 0.66 x 1.5 mm3.  Additional scan parameters were: 
TR/TE/q= 5.3ms/2.1ms/15°. 25 views per segment were acquired, in a ky-centric 
order.  
 
LGE in the LA was described by its subjective presence or absence in 18 
locations (4 around each pulmonary vein, the posterior wall, and the inter-atrial 
septum), resulting in a semi-quantitative LGE score, which is scaled to 100 
(Figure 1).  Quantitative measurement of LGE volume was also performed using 
a threshold of 3.5 SDs above the mean blood pool. Inter and intra rater reliability 
of this method has shown to be good in other similar studies36 and all LGE 
analysis was conducted by an experienced rater who was blinded to clinical data.  
The volume of segmented LGE enhancement was obtained using summation of 
segmented areas of enhancement in each axial slice (Figure 2).  
 
Subjects were also imaged with cine steady state free precession two chamber 
and four chamber views, and with a short axis stack of the left ventricle from the 
apex to the base.  Scan parameters include: Balanced SSFP cine with 
retrospective ecg-triggering, TR/TE/flip=3ms/1.5ms/60°, 30 cardiac phases.  1.4 




end-systolic volume were approximated by the biplane area-length method37 
(Figure 5b) and used to quantitate LA EF. An extension of this method was used 
to estimate the total volume of LA tissue at end-diastole with an assumed 
average left atrial wall thickness of 2.1mm38 and the surface area of the LA 
modeled as a scalene ellipsoid. LA LGE volume as quantitated above was 
divided by total LA tissue volume to calculate an LA fibrosis percentage. 
 
Assessment of active and passive atrial function. 
In a subset of the first 42 consecutive subjects in the entire cohort who did not 
have AF, LA volume throughout the entire cardiac cycle was measured, also 
using the biplane method. Only the first 42 of 101 total non-AF subjects where 
used due to the time intensive nature of this method. Atrial emptying was divided 
into passive and active phases based on changes in slope of the time volume 
curve.  The active and passive EF were then calculated (Figure 3)39.   In the 
same subset, left ventricular volumes were also quantified using Simpson’s 
method (summation of discs) across the cardiac cycle and used to construct a 
ventricular volume vs. time curve with a MATLAB (The Mathworks, Natick MA) 
spline fitting function. From this curve, a derivative curve was constructed and 
used to calculate peak filling rate, time to peak filling rate, and early to late filling 
rate ratio (E:A)30 (Figure 4). Percent length of diastole to recover 60% of 
ventricular stroke volume (DVR) was calculated from the original volume vs time 




slice. These LV metrics of diastolic function were used to adjust for the well-
known impact of diastolic function on passive LA function.    
 
Assessment of mitral regurgitant fraction (MRF) 
In a subset that included all subjects with AF (n=35; one AF subject lacked a 
phase contrast sequence), mitral regurgitation was quantified as a fraction of 
ventricular stroke volume. To calculate this value, ventricular endocardial borders 
were contoured at end systole and end diastole using a semi-automatic threshold 
detection technique that excluded ventricular trabeculations and papillary 
muscles from volume measurements. Because of the nature of this method for 
determining mitral regurgitant fraction, it was essential to include the basal slices 
of the heart when calculating these volumes. Similar to the above, Simpson’s 
method was used to calculate the ventricular volumes from these contours and 
the difference between these volumes was the stroke volume. Forward flow 
through the aorta was quantified using phase contrast imaging during ventricular 
systole. By process of exclusion in normal cardiac anatomy, ventricular stroke 
volume that does not flow forward through the aorta must be flowing retrograde 
through the mitral valve into the LA. As such, the mitral regurgitant volume is the 
ventricular stroke volume minus the aortic forward flow, and was represented as 
a percentage of the ventricular stroke volume. 
All image post processing was done using Circle Cardiovascular Imaging 






In this retrospective review, the clinical data gathered included sex, weight, 
height, smoking status, and other attributes of past medical history with specific 
attention to cardiovascular disease and risk factors. Not all study data was 
available for all subjects, and subjects were included in each analysis only when 
pertinent data were available in the record (Table 3). An incomplete record 
resulted from some patients who were referred to this institution for imaging by 
providers outside of the network; there is no chart in our EMR for such patients. 
Finally a reference group was identified from the entire 137 member cohort using 
a predetermined set of criteria: No structural or myopathic cardiac disease, no 
atrial fibrillation, no more than mild mitral regurgitation, no diagnosed coronary 
disease if subject has had a cardiac catheterization, LV EF >45%, and LV EDV 
index <90 ml/m2. Twenty-three reference subjects fit these criteria. These were 
usually subjects referred for work-up of suspected arrhythmogenic RV 
cardiomyopathy or cardiac sarcoidosis whose MRI was negative for signs of such 
pathology. 
Statistics 
In describing the relationship between LA LGE with clinical and cardiac variables, 
LGE was analyzed as a percentage of estimated LA tissue volume and as a 
semi-quantitative LGE score. Analysis using both metrics of LGE was done to 
determine whether there are differences in the ability of each to find trends, as 
each is different in its quantification of different patterns of LGE (see discussion). 




with vs. without varying conditions while Mann-Whitney tests were used for 
similar comparison of LGE scores. Pearson correlations were used to describe 
the relationship between continuous variables such as age, LA volume, atrial and 
ventricular emptying and filling measures, and LGE tissue percentage while 
Spearman correlations were used for similar analyses of LGE score. A least 
squares multivariate regression was used to describe the relationships of clinical 
conditions with the percentage of LA LGE. Clinical conditions in the model were 
chosen based on a threshold of p <0.1 in the univariate analysis. Separately, 
multivariate adjustment for ventricular filling dynamics was made to describe the 
relationship among LA LGE tissue percentage and atrial passive emptying. 
Similar analysis of ventricular filling and atrial emptying was conducted using 
LGE score quartiles. Square root or logarithmic transformations were used to 
allow for parametric analysis of otherwise non-normally distributed continuous 
data. All statistical analyses were performed using JMP v11 (SAS Institute, Cary 
NC). 
Contributions of colleagues 
Dana Peters: Provided initial direction of research inquiry, provided data from 
pilot study, quantified LGE score and LGE tissue percentage, provided ongoing 
feedback regarding analyses and future directions 
Lauren Baldassarre: provided continuing feedback on direction of the project, 
verified phase contrast forward flow measures and ventricular contours for 




Karl Grunseich: Conducted all other aspects of the project including: expanding 
scope of the research question, identification of new subjects, clinical chart 
review, imaging report review, contouring of the atrial and ventricular borders of 
subjects in each respective analysis, post-processing of atrial and ventricular 
volume-time data, all statistical analysis. 
 
Results 
Measurement of LA LGE: Quantitative vs. Semi-quantitative.  
Our two measurements of LA LGE are not equivalent to each other. LA LGE 
scores are more representative of the distribution of fibrosis across the LA; they 
indicate the percentage of 18 different possible regions that show enhancement. 
Left atrial fibrosis percentage is a measurement of volume of enhanced tissue 
relative to total atrial tissue. This measure may represent a single large area of 
enhancement in a way that is similar to many small, scattered regions of 
enhancement. Although these measurements indicated different aspects of the 
enhancement pattern, they are strongly correlated to each other (rs = 0.699, P < 
0.001 Figure 6).  The fully quantitative method required ~5 minutes of analysis, 
vs. <1 minute for the semi-quantitative method.  
 
Association with clinical conditions 
The study population was 59% male, with a mean age 51.3 (SD 13.8), a mean of 
BMI 28.5 (SD 5.9), and a diverse distribution of cardiovascular disease and risk 





There is a moderate but significant correlation between age and percentage of 
atrial tissue enhancement (r = 0.359 p < 0.001). In univariate analysis of each 
clinical factor considered within the entire cohort, only subjects with CHF or any 
mitral regurgitation had greater percentage of LA tissue enhancement than those 
without those conditions (Table 4a). In a multivariate regression including HCM, 
CHF, AF and mitral regurgitation, HCM and CHF were independently associated 
with increased LA LGE (Table 4b). Continuous variables of age and LA EF were 
not included in the multivariate analysis as they are closely associated with CHF 
and AF, causing concerns of multicollinearity. When compared to the relatively 
healthy reference subjects, those with HCM, CHF, greater than mild mitral 
regurgitation and AF all had significantly higher LA LGE tissue percentages 
(Table 5, Figure 2). We did not find any relationships with risk factors of 
cardiovascular disease, such as hypertension, obesity, or diabetes, and LA LGE. 
LGE Score 
There is a weak, non-significant correlation between age and LGE score (rs = 
0.147 p = 0.087). In univariate analysis of each clinical factor considered within 
the entire cohort, only subjects with CHF or HCM had greater percentage of LA 
tissue enhancement than those without those conditions (Table 6). A multivariate 
regression including HCM and CHF had a statistically significant lack of fit test (p 
= 0.042). Continuous variables of LA EF or LA volumes were not included in the 
multivariate analysis as they are closely associated with CHF, causing concerns 




those with HCM, CHF, greater than mild mitral regurgitation and AF all had 
significantly higher LA LGE scores (Table 5, Figure 2). We did not find any 
relationships with risk factors of cardiovascular disease, such as hypertension, 
obesity, or diabetes, and LA LGE score. 
 
Association with atrial size and function 
LGE percentage 
Across all subjects, there was a weak to moderate but significant correlation 
between both maximum and minimum LA volume and LA LGE percentage 
(Figure 7,Table 7). These relationships were also similar for subjects with and 
without atrial fibrillation (Table 7). Additionally, there was a moderate correlation 
between overall LA ejection fraction and LA LGE percentage that was similar in a 
subset of subjects with and without atrial fibrillation (Table 7).  
LGE Score 
Across all subjects, there was a weak to moderate but significant correlation 
between both maximum and minimum LA volume and LA LGE score (Figure 7, 
Table 7). These relationships were also similar for subjects with and without atrial 
fibrillation, although statistical significance was not achieved from AF subjects 
(Table 7). Additionally, there was a moderate correlation between overall LA 
ejection fraction and LA LGE score that was similar in a subset of subjects with 
and without atrial fibrillation (Table 7).  
 





In a subset of 42 subjects without AF, there was no direct relationship between 
peak filling rate, time to peak filling rate, and proportion of diastole to 60% 
diastolic volume recovery with LA LGE tissue percentage (r = -0.168 p = 0.288, r 
= 0.036 p = 0.820, r = 0.139 p = 0.380 respectively). There were strong 
correlations between both ventricular peak filling rate and time to peak filling rate 
with passive atrial ejection fraction (r = 0.723 p < 0.001; r = -0.502 p < 0.001 
respectively). Increasing LA LGE tissue percentage and peak filling rate were 
independently associated with decreasing and increasing passive LA EF 
respectively, while time to peak filling rate was not (Table 8). There was also a 
lower active atrial ejection fraction in subjects with increasing LA LGE tissue 
percent (r = -0.438 p = 0.004).   
There was no relationship between LV EF and LA LGE (r = 0.071 p=0.418). 
However, among patients with CHF and preserved EF (EF>45%) there was 
greater LA LGE percentage compared to those with lower LV EF (p = 0.032, 
Figure 8).  
LGE Score 
There was no direct relationship between LGE score and markers of diastolic 
dysfunction (including PFR, time to PFR, or proportion of diastole to 60% 
diastolic volume recovery; rs = 0.072 p = 0.653, rs = -0.015 p = 0.925, rs = -0.067 p 
= 0.675 respectively). After adjustment for the relationship of PFR and time to 
PFR with passive atrial EF, those subjects in the highest LA LGE quartile had 




LGE quartiles (p=0.020; Figure 9). In multivariate analysis, PFR (p < 0.001) but 
not time to PFR (p = 0.063) was independently associated with passive LA EF. 
There was also a lower active atrial ejection fraction in subjects in the highest 
compared to the lowest LA LGE quartile (p = 0.047).  
There was no relationship between LV EF and LA LGE score (rs = -0.032 p = 
0.711). Among patients with CHF and preserved EF (EF>45%) there was no 
difference in LA LGE score compared to those with lower LV EF (p = 0.085).  
 
Association of LGE with mitral regurgitation in subjects with AF 
In a sub-study of 35 AF subjects, we investigated the hypothesis that AF patients 
have greater remodeling in the presence of mitral regurgitation (MR).  Subject 
characteristics were 69% male, mean age 56.4±10.1, mean BMI 30.0 ±5.3, 51% 
hypertensive, 20% congestive heart failure, and 14% diabetic. MR was visualized 
in 60% of subjects (16 mild, 3 moderate, 2 not described). The presence of visual 
MR was associated with increased maximum LA volume (p = 0.001) and 
increased MRF (p = 0.022, Figure 10). Maximum LA volume was poorly 
associated with quantitative MRF (r = 0.232, p = 0.186).  
LGE percentage 
The presence of visual MR was not associated with higher LA LGE percentage 
(p = 0.307). Maximum LA volume was weakly and not significantly associated 
with LA LGE percentage (r = 0.221, p = 0.201). Direct association between MRF 




LA volume did not impact the relationship between MRF and LA LGE percentage 
(rp = 0.108 p = 0.590).   
 
LGE Score 
The presence of visual MR was not associated with higher LA LGE score (p = 
0.672). Maximum LA volume was not associated with LA LGE score (rs = 0.146, 
p = 0.402). Direct association between MRF and LA LGE score (rs = 0.140 p = 
0.430) was also not observed.  After adjustment for LA volume, increased MRF 
was not correlated with LA LGE score (rp = 0.047 p = 0.803). 
 
Discussion 
Quantitative vs. semi-quantitative assessments 
The quantification of LA LGE remains a relatively controversial area within the 
field of cardiac MRI. The current “gold standard” involves contouring the 
endocardial and epicardial border of the atrial tissue in each axial reconstructed 
slice. The enhancement threshold above the blood pool is then applied to the 
contoured atrial tissue, and both the enhanced and unenhanced areas are 
summed across all slices to calculate the fraction of atrial tissue that is 
enhanced. This process is incredibly time intensive and, if the service is provided 
by a third party, expensive. In this study we used two different methods of LGE 
quantification of varying simplicity. The tissue percentage we calculated in this 
study approximates the gold standard by estimating the volume of the total atrial 




volume of the enhanced tissue is calculated directly. This measure does not 
distinguish well between a single large area of fibrosis and several smaller, 
scattered areas of fibrosis, but is a relatively robust indicator of total atrial fibrosis 
burden. The LGE score we used is more subjective, as it is based on an 
experienced rater’s interpretation of enhancement in 18 pre-determined regions 
of the LA. It also is a better indicator of the overall spacial extent of LA LGE, but 
may understate one or two large but confined areas of LGE. This score 
assessment can be made relatively quickly, easily, and without the expense of 
external proprietary processing. The ultimate goal of this research is for the LA 
LGE protocol to be used clinically if the sequence is found to add value to patient 
prognosis and management. These features of the LGE score make it an 
attractive measure in the clinical arena.  
 
We found there to be a strong correlation between the two LA LGE measures 
used in this study. This indicates that subjects with an increased amount of LA 
LGE tend to have that LGE be distributed broadly throughout the LA instead of 
confined to one or two regions. This agreement also gives support to the use of 
the LGE score as an easier method of LGE quantification. However, there were 
some differences in the conditions and functional metrics each measure of LGE 
was associated with. On univariate analysis for example, LGE score was 
significantly greater in subjects with HCM while LGE percentage was not. Also, 
LGE percentage was greater in subjects with mitral regurgitation and marginally 




differences in how atrial fibrosis is distributed in the LA among these conditions. 
For example, subjects with mitral regurgitation may not have a wider distribution 
of LGE in the LA than those without, but do have more LGE in the regions where 
they do have enhancement. Also, subjects with HCM do have greatly elevated 
LGE scores that indicated the atrial fibrosis is wide-spread, rather than confined 
to one area as could be interpreted from the LGE percentage.  
 
It is important however, not to overlook how the subjective nature of the LGE 
score and the multitude of statistical tests done on this data set, which may 
increase the odds of false positive results. A decision was made not to use a 
Bonferroni correction in these analyses because this would severely limit our 
ability to find any differences in this relatively small population in a largely 
hypothesis generating study meant to guide future research. In order to avoid 
confusion for the remainder of the discussion, results referenced will be from the 
slightly more quantitative and robust LGE percentage. 
 
Atrial LGE, Clinical Conditions, and Cardiac Structure 
The main finding of this study is an increased extent of atrial LGE in patients with 
CHF, HCM, mitral regurgitation, and/or AF compared with the control group. In 
pathology studies, many of these cardiac diseases have been individually 
associated with increased atrial fibrosis. For example, LA fibrosis and 
electrophysiological remodeling have been demonstrated to provide a substrate 




associated with atrial fibrosis by pathology40, and it is known that CHF is 
associated with increased incidence of AF with prevalence as high as 44%41 in 
this group of patients. Previous studies of atrial fibrosis by LA LGE have nearly 
exclusively examined patients with AF. A recent study did find a correlation of 
LGE with structural heart disease in general but did not focus on specific disease 
states36. In this study, we demonstrated that atrial fibrosis can be detected by LA 
LGE MRI in subjects without AF who have CHF, HCM, or mitral regurgitation, a 
finding which could have implications for future management of patients with 
these conditions.   
 
Atrial LGE is only mildly associated with maximum LA size, but moderately 
associated with minimum LA size and LA EF in this study.  Prior studies have 
shown that minimum atrial volume is a stronger correlate with AF development, 
adverse cardiovascular events, and NT-proBNP, compared with maximum 
volume42-44.  Similarly, minimum atrial volume is more strongly correlated with 
atrial LGE in this study.   
 
Although a relationship with atrial volume exists, LA LGE is not simply a 
surrogate for LA volume.  Factors such as atrial size have been shown to be tied 
with outcomes in patients with heart failure45 and LA LGE could provide 
additional new prognostic or decision guiding data in the management of these 
patients that LA size alone does not. For example, within AF subjects Daccarett 




score for determining stroke risk. Analogously, the risk of developing AF in CHF 
patients could include LA LGE as a valuable predictor. Also, ACE inhibitors can 
reduce atrial fibrosis and mitigate the risk of AF development46.  The presence of 
LA LGE in a patient without AF could be a factor in selecting patients who would 
benefit from initiating these drugs or in dose adjustment for patients who are 
already taking them. These possible prognostic and clinical uses for measuring 
LA LGE need further study. 
 
Although there were a small number of subjects with HCM, those subjects had 
substantially higher LA LGE percentages compared to others in the reference 
group. To date, studies of LGE in hypertrophic cardiomyopathy have primarily 
been limited to ventricular LGE. Such studies have shown ventricular LGE to be 
related to AF47 and diastolic dysfunction48,49. HCM in general has a strong 
relationship with atrial fibrillation and heart failure, with increased LA size and 
decreased LA function associated with particularly high AF risk27,50and worse 
heart failure symptoms51. Measurement of LA LGE in this population of patients 
could provide similar clinical value as for CHF regarding risk assessment, 
management, and prognostic value. As with CHF, further study is needed in a 
larger population of these patients to identify risks or prognosis independently 
associated with LA LGE. 
 
Cochet et al36 found age to be an independent predictor of LA LGE.  We also 




association was weaker. Since conditions associated with increased LA LGE 
(CHF, AF) are also associated with increasing age, we were not able to establish 
an independent effect of age due to concerns of multicollinearity. Additionally, we 
were not able to establish an independent association of AF with LA LGE, 
although LGE was greater in the AF group than the healthy reference group. This 
may have been due to our relatively smaller cohort compared to other studies or 
due to a cohort with more paroxysmal vs. persistent AF patients, as persistent AF 
has been associated with greater LA LGE19. Our study also did not demonstrate 
any direct relationship with other cardiovascular risk factors  (e.g. hypertension or 
hyperlipidemia) or subject sex with the burden of LA fibrosis by LGE. These 
conditions may not be strongly associated with fibrosis on their own, or such an 
association may not be able to be detected by LA LGE in a study of this size and 
type. 
 
Atrial LGE and Atrio-Ventricular Dynamics 
The recognition of diastolic dysfunction as a potential risk factor for AF is gaining 
strength28.  Increased LA LGE in AF, HCM and CHF –all associated with diastolic 
dysfunction—suggests that there may be a more general association of left 
ventricular dynamics and LA LGE, especially as both the current and other 
studies51 have demonstrated close association between ventricular function and 
atrial filling and emptying dynamics. Across a diverse subset of patients without 
AF, we demonstrated that LA LGE was associated with reduced active and 




Additionally, in the study as a whole, there is an association of decreased overall 
LA ejection fraction with increased LA LGE. Together these results suggest LA 
LGE detected fibrosis is a marker of poor atrial function. In patients with altered 
systolic or diastolic ventricular function, it may be development of atrial fibrosis 
that further decreases the atrial contribution to overall cardiac function, potentially 
contributing to patients’ heart failure symptoms. Our finding of increased LA LGE 
in patients with heart failure but preserved LV EF supports this hypothesis.  
 
Lack of correlation between diastolic function and atrial LGE 
What remains poorly demonstrated is whether ventricular dysfunction itself can 
be directly related to left atrial fibrosis. In the current study, we did not find a 
direct correlation between ventricular diastolic filling parameters and LA LGE, 
although we were limited by a smaller sample size and the retrospective nature 
of this study. Initially, we had intended to establish the grade of diastolic 
dysfunction for the subjects for whom we calculated the diastolic filling 
parameters. However, this was not possible because we lacked the ability to 
distinguish between normal diastolic filling and grade 2 or “pseudonormal” 
diastolic filling. This problem arises because of how the measures of ventricular 
filling change as diastolic dysfunction progresses. With impaired relaxation there 
is an initial decrease in early peak filling rate and an increase in time to peak 
filling rate. As diastolic dysfunction progresses and the ventricle stiffens, this 
change reverses and the peak filling rate increases and time to peak filling rate 




dysfunction when these numbers appear normal. In echocardiography, there are 
well-established parameters based on measures of tissue movement that can 
distinguish true from pseudo normal. Unfortunately, MRI currently lacks such 
distinguishing measures as even the measures of diastolic dysfunction unique to 
MRI, e.g. proportion of diastole to 60% diastolic volume recovery, change in a 
way similar to time to peak filling rate. Once a reliable distinguishing measure is 
established that can be applied to previously acquired images for MRI, it will be 
useful to revisit this subject population and stratify the grade of diastolic 
dysfunction and look for patterns of LA LGE. 
 
MRF is not correlated with LGE among AF subjects 
In examining the subjects with AF in our study, we did not find any measures of 
mitral regurgitation to be associated with LA LGE score or tissue percentage. It is 
well established that many patients with AF have LA LGE, and our intent was to 
find whether mitral regurgitation moderates or amplifies the quantity of LA LGE in 
these AF subjects. There is a growing body of literature of correlates of LA LGE 
in AF studies much larger than ours which have found atrial functional measures, 
time in AF, and pattern of AF to be associated with LGE quantity19,20. Given that 
these factors are known to influence the amount of LGE in the LA, it is 
reasonable for us not to find an association of mitral regurgitation without first 
being able to adjust for these other factors (we lacked adequate data in this 




regurgitation is relatively weak, as might be the case in our data set as most 
subjects had mild, if any, regurgitation. 
 
Conclusion 
In assessments of LA LGE in a diverse population, we found that extent of LGE 
correlates with the presence of CHF, AF, HCM, mitral regurgitation, and age, 
though independence could be established only for CHF and HCM.  We also 
found moderate relationships between LA LGE and LA volume, LA active EF, 
and LA passive EF, after accounting for ventricular diastolic function. Each of 
these findings of association of LA LGE with cardiac conditions and functional 
metrics lays the groundwork for further inquiry into the utility of measuring LA 
LGE in subjects beyond those with AF. 
 
In particular, a prospective study following patients with CHF or HCM with initial 
and follow-up LGE images and quantification could be fruitful, especially if 
patients were also followed with periodic holter monitoring to document 
development of atrial fibrillation. Such a study could determine variables that lead 
to greater progression of LGE burden and detect whether LGE burden is related 
to risk of AF. An additional study could also include an analysis to examine 
whether patients’ medications, such as ACE inhibitors, influence LGE burden. 
With the results of this study, the need to further evaluate the value of LA LGE 





























































































































































































Figure 1. (A) Schematic of 18 regions in the LA used to quantify the presence 
of LA LGE included Anterior Superior (AS), Posterior Superior (PS), Anterior 
Inferior (AI), and Posterior Inferior (PI) regions around each pulmonary vein in 
addition to the posterior wall and interatrial septum. (B) Sample LGE image 
indicating two regions of enhancement (red arrows). Corresponding axial slice 
and enhanced regions indicated in A. Without enhancement in other planes, 




























Figure 2. Four subjects with LA LGE, showing a single slice, and the 3D 
rendering of LGE (red) and normal tissue (blue). Subject A is a relatively 
healthy reference subject while subjects B, C, and D have atrial fibrillation, 
hypertrophic cardiomyopathy, and congestive heart failure, respectively. 
	
	 40	
Table 1. Independent Risk Factors for New Onset of Atrial 
Fibrillation in Older Adults (adapted from Psaty et al. 
Circulation 1997. 96:7 2455-61) 
Variable RR 95% CI 
Alcohol, drinks/wk 0.96 0.93-0.99 
Systolic BP, 10 mm Hg 1.11 1.05-1.18 
Height, cm 1.03 1.02-1.05 
Cholesterol, mmol/L 0.86 0.76 -0.98 
Age, y 1.05 1.03-1.08 
Glucose, mmol/L 1.08 1.03-1.13 
Valve disease 2.42 1.62-3.60 
β-Blockers 0.61 0.41-0.91 
Diuretics 1.51 1.17-1.97 
Coronary disease 1.48 1.13-1.95 
Cardiac injury score 1.01 1.00-1.02 
FEV1, L 0.75 0.59 -0.94 
Left atrial size, cm 1.74 1.44-2.11 
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Figure 3. Representative curve of LA volume during the cardiac cycle with 
























Figure 4. Representative curve of left ventricular volume (left) and its 
derivative (right) during 30 phases (time points) of the cardiac cycle with 
measures of diastolic function indicated. Diastolic volume recovery (DVR) is 
the proportion of diastole required for the ventricular volume to return to X% 
of the end diastolic volume. The “E” peak is the early peak filling rate (PFR), 















Figure 5. Screen capture of circle cardiovascular imaging software as used for 
post processing to (A) determine left ventricular volumes over the cardiac 
cycle and (B) estimate maximum (upper images) and minimum (lower images) 
atrial volumes. Note the clear distinction of the endocardial border (red) and 
papillary muscles (purple) in A. In B, the formula used to estimate volume is 
Vol = 0.001 x (0.85 x 2 chamber atrial area (at left) x 4 chamber atrial area (at 































































Age 51.3 (13.8) 0 




male 81 (59%) 0 
female 56 (41%) 0 
Atherosclerosis Risk Factors 
 
 
Tobacco Use 42 (37%) 23 
Hyperlipidemia 53 (47%) 24 
Hypertension 61 (48%) 11 
Diabetes 14 (11%) 12 
Selected Cardiac Disease 
 
 
Hypertrophic Cardiomyopathy 6 (4%) 0 
Congestive Heart Failure 19 (14%) 4 
Atrial Fibrillation 36 (28%) 7 
Mitral Regurgitation 52 (38%) 0 
Medication Usage* 
  Beta-Blocker 48 (38%) 9 
Calcium Channel Blocker 18 (14%) 9 
ACE-Inhibitor 30 (23%) 9 
Aspirin 45 (35%) 9 
Statin 35 (27%) 9 
Anti-arrhythmetic 17 (13%) 9 
* at time of imaging 
  % considering only patients for whom data was 
available 


















Figure 6. The quantitative LGE percentage of LA tissue volume is strongly 
correlated to subjective, semi-quantitative LA LGE score (rs = 0.699 p < 0.001). 
x with AF 
• without AF 




















Condition	 	 LGE	%	 p	 LGE	%	 p	 LGE	%	 p	
Obesity	 +	 4.2	(0.6)	 0.51	 4.6	(1.0)	 0.14	 4.1	(0.8)	 0.92	-	 4.8	(0.7)	 7.7	(2.1)	 4.2	(0.7)	
Gender	 male	 4.4	(0.6)	 0.83	 4.8	(0.8)	 0.14	 4.2	(0.8)	 0.65	female	 4.6	(0.8)	 9.4	(3.5)	 3.7	(0.6)	
Atherosclerosis	Risk	Factors	
	 	 	 	 	 	 	
Tobacco	Use	 +	 4.3	(0.9)	 0.47	 4.9	(1.6)	 0.41	 4.1	(1.0)	 0.9	-	 5.0	(0.7)	 6.6	(1.4)	 4.3	(0.7)	
Hyperlipidemia	 +	 4.3	(0.7)	 0.28	 4.1	(1.1)	 0.06	 4.3	(0.8)	 0.97	-	 5.4	(0.9)	 8.0	(1.8)	 4.3	(0.9)	
Hypertension	 +	 5.1	(0.8)	 0.34	 5.4	(1.6)	 0.45	 5.0	(0.9)	 0.19	-	 4.1	(0.7)	 7.0	(1.5)	 3.5	(0.8)	
Diabetes	 +	 5.6	(1.5)	 0.44	 7.4	(2.5)	 0.58	 4.7	(2.0)	 0.72	-	 4.4	(0.5)	 5.9	(1.2)	 4.1	(0.6)	
Selected	Cardiac	Disease	







0.06	-	 4.2	(0.4)	 6.1	(1.1)	 3.7	(0.5)	
Congestive	Heart	Failure	 +	 9.5	(1.6)	 <0.01	 10.1	(2.7)	 0.08	 9.1	(2.1)	 <0.01	-	 3.8	(0.5)	 5.3	(1.1)	 3.4	(0.5)	
Atrial	Fibrillation	 +	 6.1	(1.1)	 0.06	 N/A	 N/A	 N/A	 N/A	-	 4.0	(0.5)	 N/A	 N/A	























	 	 	 	Hypertrophic	Cardiomyopathy	 61	(38-74)	 <0.001	 10.5	(3.9)	 0.021	
Congestive	Heart	Failure	 33	(22-44)	 <0.001	 9.5	(1.6)	 <0.001	
Atrial	Fibrillation	 17	(6-42)	 0.013	 6.1	(1.1)	 0.001	





























Condition	 	 LGE	Score	 p	 LGE	Score	 p	 LGE	Score	 p	
Obesity	 +	 11	(6-28)	 0.35	 17	(6-33)	 0.30	 11	(6-28)	 0.57	-	 17	(6-33)	 28	(6-46)	 17	(6-33)	
Gender	 male	 17	(6-33)	 0.76	 17	(8-39)	 0.63	 11	(6-33)	 0.49	female	 17	(6-32)	 17	(0-44)	 17	(11-28)	
Atherosclerosis	Risk	Factors	
	 	 	 	 	 	 	
Tobacco	Use	 +	 11	(4-29)	 0.24	 11	(4-32)	 0.27	 11	(1-32)	 0.51	-	 17	(7-33)	 19	(10-44)	 17	(6-33)	
Hyperlipidemia	 +	 11	(6-28)	 0.44	 17	(6-33)	 0.70	 11	(6-28)	 0.52	-	 17	(6-33)	 28	(1-44)	 17	(6-33)	
Hypertension	 +	 17	(6-28)	 0.71	 17	(6-33)	 0.20	 17	(6-28)	 0.87	-	 17	(6-33)	 28	(11-44)	 11	(6-33)	
Diabetes	 +	 11	(6-22)	 0.65	 17	(8-36)	 0.96	 11	(6-17)	 0.44	-	 17	(6-33)	 17	(6-44)	 17	(6-33)	
Selected	Cardiac	Disease	
	 	 	 	 	 	 	
Hypertrophic	Cardiomyopathy	 +	 61	(38-74)	 <0.01	 N/A	 N/A	 61	(38-74)	 <0.01	-	 17	(6-33)	 17	(6-42)	 17	(6-28)	
Congestive	Heart	Failure	 +	 33	(22-44)	 <0.01	 33	(22-44)	 0.05	 36	(15-43)	 <0.01	-	 14	(6-28)	 11	(6-33)	 17	(6-28)	
Atrial	Fibrillation	 +	 17	(6-42)	 0.57	 N/A	 N/A	 N/A	 N/A	-	 17	(6-33)	 N/A	 N/A	









































x , ---  with AF 
• ,       without AF 
Figure 7. Associations of LA volumes and ejection fraction with measures of LA 
























Maximum	LA	volume	 0.240	 0.005	 0.197	 0.022	 0.135	 0.433	 0.178	 0.299	 0.235	 0.024	 0.147	 0.163	
Minimum	LA	volume	 0.346	 <0.001	 0.406	 <0.001	 0.279	 0.099	 0.349	 0.037	 0.385	 <0.001	 0.401	 <0.001	






	LA	LGE	Percentage	 -0.253	 0.137	 0.019	
Ventricular	Peak	Filling	Rate	 0.580	 0.384	 <0.001	
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Figure	9.	After	multivariate	adjustment	for	peak	filling	rate	and	time	to	peak	
filling	rate,	those	subjects	in	the	quartile	with	the	highest	LA	LGE	score	had	a	
significantly	lower	passive	LA	ejection	fraction	than	those	in	the	lowest	two	
quartiles	(p=0.020).	
1st		=	0-6			2nd	=	11-17			3rd		=	22-33			4th	=	39-100	
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Figure	10.	Visualized	mitral	regurgitation	is	associated	with	both	a	greater	
measured	mitral	regurgitant	fraction	(p=0.022)	and	indexed	maximum	left	atrial	
volume	(p=0.001).	
